Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 7 of 7 entries
Sorted by: Best Match Show Resources per page
Mutation spectrum in South American Lynch syndrome families.

Hereditary cancer in clinical practice

Dominguez-Valentin M, Nilbert M, Wernhoff P, López-Köstner F, Vaccaro C, Sarroca C, Palmero EI, Giraldo A, Ashton-Prolla P, Alvarez K, Ferro A, Neffa F, Caris J, Carraro DM, Rossi BM.
PMID: 24344984
Hered Cancer Clin Pract. 2013 Dec 18;11(1):18. doi: 10.1186/1897-4287-11-18.

BACKGROUND: Genetic counselling and testing for Lynch syndrome have recently been introduced in several South American countries, though yet not available in the public health care system.METHODS: We compiled data from publications and hereditary cancer registries to characterize the...

Cite
Dominguez-Valentin M, Nilbert M, Wernhoff P, et al. Mutation spectrum in South American Lynch syndrome families. Hered Cancer Clin Pract. 2013;11(1):18doi: 10.1186/1897-4287-11-18.
Dominguez-Valentin, M., Nilbert, M., Wernhoff, P., López-Köstner, F., Vaccaro, C., Sarroca, C., Palmero, E. I., Giraldo, A., Ashton-Prolla, P., Alvarez, K., Ferro, A., Neffa, F., Caris, J., Carraro, D. M., & Rossi, B. M. (2013). Mutation spectrum in South American Lynch syndrome families. Hereditary cancer in clinical practice, 11(1), 18. https://doi.org/10.1186/1897-4287-11-18
Dominguez-Valentin, Mev, et al. "Mutation spectrum in South American Lynch syndrome families." Hereditary cancer in clinical practice vol. 11,1 (2013): 18. doi: https://doi.org/10.1186/1897-4287-11-18
Dominguez-Valentin M, Nilbert M, Wernhoff P, López-Köstner F, Vaccaro C, Sarroca C, Palmero EI, Giraldo A, Ashton-Prolla P, Alvarez K, Ferro A, Neffa F, Caris J, Carraro DM, Rossi BM. Mutation spectrum in South American Lynch syndrome families. Hered Cancer Clin Pract. 2013 Dec 18;11(1):18. doi: 10.1186/1897-4287-11-18. PMID: 24344984; PMCID: PMC3904200.
Copy Download .nbib Format: NLM
Source document verification in the Mucopolysaccharidosis Type I Registry.

Pharmacoepidemiology and drug safety

Verhulst K, Artiles-Carloni L, Beck M, Clarke JT, Neto JC, Cox GF, Fernhoff PM, Guffon N, Kong Y, Martins AM, Tylki-Szymanska A, Whitley CB, Wijburg FA, Wraith EJ, Koepper CM.
PMID: 22170853
Pharmacoepidemiol Drug Saf. 2012 Jul;21(7):749-752. doi: 10.1002/pds.2200. Epub 2011 Dec 14.

PURPOSE: The Mucopolysaccharidosis Type I (MPS I) Registry is an international observational database that tracks the natural history and the outcomes of patients with MPS I. The Registry was a regulatory requirement following the approval of laronidase enzyme replacement...

Cite
Verhulst K, Artiles-Carloni L, Beck M, et al. Source document verification in the Mucopolysaccharidosis Type I Registry. Pharmacoepidemiol Drug Saf. 2011;21(7):749-752doi: 10.1002/pds.2200.
Verhulst, K., Artiles-Carloni, L., Beck, M., Clarke, J. T., Neto, J. C., Cox, G. F., Fernhoff, P. M., Guffon, N., Kong, Y., Martins, A. M., Tylki-Szymanska, A., Whitley, C. B., Wijburg, F. A., Wraith, E. J., & Koepper, C. M. (2012). Source document verification in the Mucopolysaccharidosis Type I Registry. Pharmacoepidemiology and drug safety, 21(7), 749-752. https://doi.org/10.1002/pds.2200
Verhulst, Karien, et al. "Source document verification in the Mucopolysaccharidosis Type I Registry." Pharmacoepidemiology and drug safety vol. 21,7 (2012): 749-752. doi: https://doi.org/10.1002/pds.2200
Verhulst K, Artiles-Carloni L, Beck M, Clarke JT, Neto JC, Cox GF, Fernhoff PM, Guffon N, Kong Y, Martins AM, Tylki-Szymanska A, Whitley CB, Wijburg FA, Wraith EJ, Koepper CM. Source document verification in the Mucopolysaccharidosis Type I Registry. Pharmacoepidemiol Drug Saf. 2012 Jul;21(7):749-752. doi: 10.1002/pds.2200. Epub 2011 Dec 14. PMID: 22170853.
Copy Download .nbib Format: NLM
Canine scent detection of canine cancer: a feasibility study.

Veterinary medicine (Auckland, N.Z.)

Dorman DC, Foster ML, Fernhoff KE, Hess PR.
PMID: 30050858
Vet Med (Auckl). 2017 Oct 26;8:69-76. doi: 10.2147/VMRR.S148594. eCollection 2017.

The scent detection prowess of dogs has prompted interest in their ability to detect cancer. The purpose of this study was to determine whether dogs could use olfactory cues to discriminate urine samples collected from dogs that did or...

Cite
Dorman DC, Foster ML, Fernhoff KE, et al. Canine scent detection of canine cancer: a feasibility study. Vet Med (Auckl). 2017;8:69-76doi: 10.2147/VMRR.S148594.
Dorman, D. C., Foster, M. L., Fernhoff, K. E., & Hess, P. R. (2017). Canine scent detection of canine cancer: a feasibility study. Veterinary medicine (Auckland, N.Z.), 869-76. https://doi.org/10.2147/VMRR.S148594
Dorman, David C, et al. "Canine scent detection of canine cancer: a feasibility study." Veterinary medicine (Auckland, N.Z.) vol. 8 (2017): 69-76. doi: https://doi.org/10.2147/VMRR.S148594
Dorman DC, Foster ML, Fernhoff KE, Hess PR. Canine scent detection of canine cancer: a feasibility study. Vet Med (Auckl). 2017 Oct 26;8:69-76. doi: 10.2147/VMRR.S148594. eCollection 2017. PMID: 30050858; PMCID: PMC6042482.
Copy Download .nbib Format: NLM
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases.

Translational oncology

Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM.
PMID: 31096111
Transl Oncol. 2019 Jul;12(7):951-958. doi: 10.1016/j.tranon.2019.04.001. Epub 2019 May 13.

Although clinical management of melanoma has changed considerably in recent years, intrinsic treatment resistance remains a severe problem and strategies to design personal treatment regimens are highly warranted. We have applied a three-dimensional (3D) ex vivo drug efficacy assay,...

Cite
Flørenes VA, Flem-Karlsen K, McFadden E, et al. A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases. Transl Oncol. 2019;12(7):951-958doi: 10.1016/j.tranon.2019.04.001.
Flørenes, V. A., Flem-Karlsen, K., McFadden, E., Bergheim, I. R., Nygaard, V., Nygård, V., Farstad, I. N., Øy, G. F., Emilsen, E., Giller-Fleten, K., Ree, A. H., Flatmark, K., Gullestad, H. P., Hermann, R., Ryder, T., Wernhoff, P., & Mælandsmo, G. M. (2019). A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases. Translational oncology, 12(7), 951-958. https://doi.org/10.1016/j.tranon.2019.04.001
Flørenes, Vivi Ann, et al. "A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases." Translational oncology vol. 12,7 (2019): 951-958. doi: https://doi.org/10.1016/j.tranon.2019.04.001
Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM. A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases. Transl Oncol. 2019 Jul;12(7):951-958. doi: 10.1016/j.tranon.2019.04.001. Epub 2019 May 13. PMID: 31096111; PMCID: PMC6520638.
Copy Download .nbib Format: NLM
MLH1 Ile219Val Polymorphism in Argentinean Families with Suspected Lynch Syndrome.

Frontiers in oncology

Dominguez-Valentin M, Wernhoff P, Cajal AR, Kalfayan PG, Piñero TA, Gonzalez ML, Ferro A, Sammartino I, Causada Calo NS, Vaccaro CA.
PMID: 27606285
Front Oncol. 2016 Aug 24;6:189. doi: 10.3389/fonc.2016.00189. eCollection 2016.

No abstract available.

Cite
Dominguez-Valentin M, Wernhoff P, Cajal AR, et al. MLH1 Ile219Val Polymorphism in Argentinean Families with Suspected Lynch Syndrome. Front Oncol. 2016;6:189doi: 10.3389/fonc.2016.00189.
Dominguez-Valentin, M., Wernhoff, P., Cajal, A. R., Kalfayan, P. G., Piñero, T. A., Gonzalez, M. L., Ferro, A., Sammartino, I., Causada Calo, N. S., & Vaccaro, C. A. (2016). MLH1 Ile219Val Polymorphism in Argentinean Families with Suspected Lynch Syndrome. Frontiers in oncology, 6189. https://doi.org/10.3389/fonc.2016.00189
Dominguez-Valentin, Mev, et al. "MLH1 Ile219Val Polymorphism in Argentinean Families with Suspected Lynch Syndrome." Frontiers in oncology vol. 6 (2016): 189. doi: https://doi.org/10.3389/fonc.2016.00189
Dominguez-Valentin M, Wernhoff P, Cajal AR, Kalfayan PG, Piñero TA, Gonzalez ML, Ferro A, Sammartino I, Causada Calo NS, Vaccaro CA. MLH1 Ile219Val Polymorphism in Argentinean Families with Suspected Lynch Syndrome. Front Oncol. 2016 Aug 24;6:189. doi: 10.3389/fonc.2016.00189. eCollection 2016. PMID: 27606285; PMCID: PMC4996012.
Copy Download .nbib Format: NLM
Clinic-based infant screening for duchenne muscular dystrophy: a feasibility study.

PLoS currents

Cyrus A, Street N, Quary S, Kable J, Kenneson A, Fernhoff P.
PMID: 22866242
PLoS Curr. 2012 May 02;e4f99c5654147a. doi: 10.1371/4f99c5654147a.

Purpose. The purpose of this study was to assess the desirability of Duchenne muscular dystrophy (DMD) screening, the effectiveness of the consent process, and the feasibility of conducting DMD screening in a pediatric office. Methods. Infant males who attended...

Cite
Cyrus A, Street N, Quary S, et al. Clinic-based infant screening for duchenne muscular dystrophy: a feasibility study. PLoS Curr. 2012;e4f99c5654147adoi: 10.1371/4f99c5654147a.
Cyrus, A., Street, N., Quary, S., Kable, J., Kenneson, A., & Fernhoff, P. (2012). Clinic-based infant screening for duchenne muscular dystrophy: a feasibility study. PLoS currents, e4f99c5654147a. https://doi.org/10.1371/4f99c5654147a
Cyrus, Alissa, et al. "Clinic-based infant screening for duchenne muscular dystrophy: a feasibility study." PLoS currents vol. (2012): e4f99c5654147a. doi: https://doi.org/10.1371/4f99c5654147a
Cyrus A, Street N, Quary S, Kable J, Kenneson A, Fernhoff P. Clinic-based infant screening for duchenne muscular dystrophy: a feasibility study. PLoS Curr. 2012 May 02;e4f99c5654147a. doi: 10.1371/4f99c5654147a. PMID: 22866242; PMCID: PMC3392140.
Copy Download .nbib Format: NLM
Dysregulation of MITF Leads to Transformation in MC1R-Defective Melanocytes.

Cancers

Lavelle TJ, Alver TN, Heintz KM, Wernhoff P, Nygaard V, Nakken S, Øy GF, Bøe SL, Urbanucci A, Hovig E.
PMID: 32605315
Cancers (Basel). 2020 Jun 28;12(7). doi: 10.3390/cancers12071719.

The MC1R/cAMP/MITF pathway is a key determinant for growth, differentiation, and survival of melanocytes and melanoma. MITF-M is the melanocyte-specific isoform of Microphthalmia-associated Transcription Factor (MITF) in human melanoma. Here we use two melanocyte cell lines to show that...

Cite
Lavelle TJ, Alver TN, Heintz KM, et al. Dysregulation of MITF Leads to Transformation in MC1R-Defective Melanocytes. Cancers (Basel). 2020;12(7)doi: 10.3390/cancers12071719.
Lavelle, T. J., Alver, T. N., Heintz, K. M., Wernhoff, P., Nygaard, V., Nakken, S., Øy, G. F., Bøe, S. L., Urbanucci, A., & Hovig, E. (2020). Dysregulation of MITF Leads to Transformation in MC1R-Defective Melanocytes. Cancers, 12(7), . https://doi.org/10.3390/cancers12071719
Lavelle, Timothy J, et al. "Dysregulation of MITF Leads to Transformation in MC1R-Defective Melanocytes." Cancers vol. 12,7 (2020). doi: https://doi.org/10.3390/cancers12071719
Lavelle TJ, Alver TN, Heintz KM, Wernhoff P, Nygaard V, Nakken S, Øy GF, Bøe SL, Urbanucci A, Hovig E. Dysregulation of MITF Leads to Transformation in MC1R-Defective Melanocytes. Cancers (Basel). 2020 Jun 28;12(7). doi: 10.3390/cancers12071719. PMID: 32605315; PMCID: PMC7408466.
Copy Download .nbib Format: NLM
Showing 1 to 7 of 7 entries